YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Amgen Inks $10.5 Billion Deal for Onyx


August 26, 2013 | Amgen agreed to acquire Onyx Pharmaceuticals on Sunday for $10.4 billion. Amgen tried to acquire the in June for $120/share, but was rejected. Yesterday's agreement was for $125/share. Onyx, based in South San Francisco, has a drug product designed to fight blood cancers. Los Angeles Times
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.